Download Dr. McGinty`s presentation at 2015 retreat

Career Development in Translational
Addiction Research
Jacqueline F. McGinty, Ph.D.
Interim Dean, College of Graduate Studies
NIDA T32 Director
Dept. of Neuroscience and
Neurobiology of Addiction Research Center
Medical University of South Carolina
Career Development in Drug Abuse Research
Predoctoral T32->F30/F31
Postdoctoral T32->F32
K Awards
•
•
•
•
•
•
•
“Fellows on NRSA grants, compared with their
colleagues without NRSA support, are more likely to
be appointed as faculty and more likely to apply for
and receive independent NIH support.”
NIDA Mentoring Guide
NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) PAR13-163 (K12) - March 28, 2013
NIH Pathway to Independence Award (Parent K99/R00) PA-14-042 (K99/R00) - December 19, 2013
Mentored Quantitative Research Development Award (Parent K25) PA-14-048 (K25) - December 19, 2013
Mentored Patient-Oriented Research Career Development Award (Parent K23) PA-14-049 (K23) December 19, 2013
Mentored Clinical Scientist Research Career Development Award (Parent K08) PA-14-046 (K08) December 19, 2013
Mentored Research Scientist Development Award (Parent K01) PA-14-044 (K01) - December 19, 2013
Independent Scientist Award (Parent K02) PA-14-045 (K02) - December 19, 2013
http://www.drugabuse.gov/funding/research-training-career-development
http://report.nih.gov/nihdatabook/index.aspx?catid=14
Kirschstein-NRSA pre-doctoral fellowships (F31)
Competing applications, awards, and success rates
Kirschstein-NRSA post-doctoral fellowships (F32)
Competing applications, awards, and success rates
Research Career Development Awards
Research Career Development Award Success Rates
NIDA Mentoring Guide
"NIDA offers a strategic set of funding mechanisms to support the development of
research scientists through various stages of their careers. These awards are designed
to ensure that scientists of the very highest caliber will be available in adequate
numbers and in the appropriate research areas and fields to meet the Nation's drug
abuse and addiction needs." – Nora D. Volkow, M.D., NIDA Director
The guide was developed over several years with the help of both mentors and
mentees. Work began at a workshop of the College on Problems of Drug Dependence
(CPDD) in 2003, continued at a career development seminar of CPDD in 2005, and
culminated at the National Institute on Drug Abuse (NIDA) Research Training Institute
in 2006.
http://www.drugabuse.gov/publications/mentoring-guide-drug-abuse-researchers/preface
NIDA Strategic Plan 2016-2020
• The current NIDA Strategic Plan was published in 2010.
Since that time, there have been major advances in the
science of drug abuse and addiction. In the Strategic Plan
for 2016–2020, NIDA seeks to harness the latest research
technologies and apply them to the ever-evolving
substance abuse landscape. Toward this goal, NIDA staff
developed a draft set of strategic priorities and are seeking
feedback to guide the development of NIDA’s Strategic
Plan.
• See more at: http://grants.nih.gov/grants/guide/noticefiles/NOT-DA-15-005.html#sthash.UuANcvIX.dpuf
NIDA Strategic Priorities 2016-2020
Basic Neuroscience: Improve our understanding of the basic science of drug
use, addiction, vulnerability to addiction, and recovery
•
•
•
•
•
•
•
•
•
•
•
•
Increase our knowledge of biological, behavioral, environmental, and developmental factors
involved in risk and resilience for drug use and addiction
Integrating animal models, behavior, genetics, epigenetics, and other molecular biomarkers for
drug abuse and addiction
Understand the developmental trajectory of addiction and individual heterogeneity
Improve our understanding of brain circuits related to drug abuse and addiction at the cellular,
circuit, and connectome levels, including:
Normal development and function across the lifespan including mechanisms of reward, selfcontrol, and conditioning
Drug effects on neuroplasticity, neural structure, and circuit function across the stages of addiction
Neurobiological correlates of recovery
Neural-glial, -immune, and neuroendocrine interactions
Better define the interactions between addiction and pain, including molecular, genetic, behavioral
, and neural-circuit-related factors, to guide the development of alternate treatment strategies for
pain patients
Improve our understanding of the interaction between addiction and co-occurring conditions
Elucidate the impact of mental health, HIV, HCV, pain, etc. on addiction;
Understand molecular mechanisms of latent HIV reservoirs in the brains of substance-abusing
populations
See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-15005.html#sthash.UuANcvIX.dpuf
NIDA Strategic Priorities 2016-2020
Clinical and Translational Science: Support the development of new and better
interventions and treatments that incorporate the diverse needs of individuals with
Substance Use Disorders (SUDs)
•
•
•
•
•
•
•
•
•
•
•
Support the development of novel, evidence-based, targeted prevention and treatment
interventions including social, behavioral, pharmacological, vaccines, and brain stimulation
therapies (e.g., transcranial magnetic stimulation, direct current stimulation, etc.)
Accelerate the identification of promising targets and ligands to accelerate new drug discovery and
development
Accelerate medications development for SUDs
Focused development efforts on:
Addictions without an FDA approved treatment
Detoxification
Overdose prevention or reversal
Accelerating neurobiological recovery
Addressing comorbidities (MH, HIV, HCV, pain)
Develop techniques to measure and improve patient compliance in clinical trials
Identify measures other than abstinence that can reliably assess SUD treatment outcomes Identify
biomarkers of addiction, resilience, and recovery to enable personalized treatment
See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-15005.html#sthash.UuANcvIX.dpuf
NIDA Strategic Plan 2016-2020
DIVERSITY:
• The demographics of students and mentees are changing continually. As the
demographic characteristics of mentees shift, so must the training of mentors.
• NOT-OD-15-053 http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15053.html Release Date: January 12, 2015 Purpose
• The purpose of this notice is to provide an updated diversity statement that
describes NIH's interest in the diversity of the NIH-funded workforce.
NEED FOR TEAM SCIENCE:
• Approaches from single disciplines have done much to advance drug abuse
research, but technological, methodological, and other advances have established
the need for increasingly multidisciplinary approaches to address more complex
questions.
Trends in race/ethnicity of NIH-supported Ph.D. recipients
White
Hispanic
Asian/Pacific Islander
Black
BIOMEDICAL RESEARCH WORKFORCE
WORKING GROUP REPORT
National Institutes of Health
June 14, 2012
US Graduate Degrees Awarded, by Field
MDs
Basic Biomedical
Years Biomedical PhDs Spend in Postdoctoral Training
Most US-trained biomedical PhDs spend fewer than 5 years in postdoctoral
positions, although that number has been grown since 2003
Biomedical Postdoctoral Researchers by Type of Support
Age at First PhD, First Non Postdoctoral Job, First Tenure Track
Job, for US trained Doctorates
First tenure-track Job
First non-postdoc Job
First PhD
Distribution of NIH RPG Principal Investigators by Degree Type
PhD
MD
MD/
PhD
Researchers with an MD or MD/PhD comprise around 30% of NIH-funded
Principal Investigators (PIs). The percentage of MDs has declined and the
percentage of MD/PhDs has increased slightly in the past few years.
Estimated Change in Employment Levels in Biomedical Occupations
Survey of Doctorate Recipients
Medical Scientists
Postsecondary
Teachers
Biological Scientists
Biochemists
Biomedical PhD Job Stats
McGinty Lab
http://academicdepartments.musc.edu/neuro-research/research/lab/McGinty_Lab/index.html